DESCRIPTION

Published quarterly, The American Journal of Preventive Cardiology is the official journal of the American Society for Preventive Cardiology. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research and reviews are published on epidemiology and clinical studies on risk factors, behavioral and pharmacologic interventions aimed at the primary and secondary prevention of cardiovascular diseases and related conditions, as well as the promotion of individual and community cardiovascular health.

The journal publishes both original research and review papers that address the key aspects of preventive cardiology, including the primary and secondary prevention of cardiovascular disease and related conditions including both behavioral (e.g., smoking, obesity, diet, and physical activity) and clinical (e.g., dyslipidemia, hypertension, and diabetes) aspects. Papers also address educational and other initiatives and methods aimed at improving the ability of cardiologists and healthcare professionals to provide effective clinical prevention and public health services. The journal also publishes guidelines and official policy statements from the Society, review articles, media reviews, and editorials. Finally, the journal periodically publishes special theme issues devoted to areas of current interest to the cardiac prevention community. Also included are editorials, readers' comments, and abstracts from the annual ASPC scientific sessions.

ABSTRACTING AND INDEXING

Directory of Open Access Journals (DOAJ)

EDITORIAL BOARD

Co-Editors-in-Chief
Erin Michos, Johns Hopkins University School of Medicine, Division of Cardiology, Baltimore, Maryland, United States of America
Cardiovascular disease prevention, Women’s health, Lipids, Physical activity, Inflammation
Nathan D. Wong, University of California, Irvine, School of Medicine, Heart Disease Prevention Program, Irvine, California, United States of America
Cardiovascular risk assessment, Dyslipidemia, Subclinical atherosclerosis, Diabetes, Primary prevention, Secondary prevention
**Associate Editors**

**Ezra Amsterdam**, University of California Davis Health System, Sacramento, California, United States of America  
Exercise testing, Exercise training, Cardiac rehabilitation, Hypertension, Lipids, Psychological stress on the Heart, Diet and CAD, Gender and heart

**C. Noel Bairey Merz**, Cedars-Sinai Medical Center, Los Angeles, California, United States of America  
Ischemic Heart Disease, Heart Disease in Women, Preventive Cardiology, Advanced Cardiac Imaging

**Harold Bays**, Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States of America  
Obesity, Preventive cardiology, Adiposopathy, Adipose tissue, Epicardial fat

**Keith Ferdinand**, Tulane Medical Center, New Orleans, Louisiana, United States of America  
Hypertension, Hyperlipidemia, Racial/ethnic disparities, Heart failure, Social determinants of health

**C. Noel Bairey Merz**, Cedars-Sinai Medical Center, Los Angeles, California, United States of America  
Ischemic Heart Disease, Heart Disease in Women, Preventive Cardiology, Advanced Cardiac Imaging

**Harold Bays**, Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky, United States of America  
Obesity, Preventive cardiology, Adiposopathy, Adipose tissue, Epicardial fat

**Keith Ferdinand**, Tulane Medical Center, New Orleans, Louisiana, United States of America  
Hypertension, Hyperlipidemia, Racial/ethnic disparities, Heart failure, Social determinants of health

**Amit Khera**, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, Dallas, Texas, United States of America  
Lipids, Prevention, Coronary calcium, Familial hypercholesterolemia, Lifestyle interventions

**Angela Maas**, Radboudumc, Nijmegen, Netherlands  
Women’s cardiovascular health, sex differences in cardiovascular disease, menopause

**Nehal Mehta**, National Heart Lung and Blood Institute, Bethesda, Maryland, United States of America  
Innate immunity, inflammation

**Michael Shapiro**, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America  
Atherosclerosis, Lipids, Lipoprotein metabolism, PCSK9, Cardiovascular disease prevention

**Laurence Sperling**, Emory University School of Medicine, Atlanta, Georgia, United States of America  
Heart disease prevention, Cardiac catheterization, Lipid metabolism, Echocardiography and LDL apheresis

**Peter P. Toth**, Johns Hopkins University School of Medicine, Ciccarone Center for the Prevention of Cardiovascular Disease, Baltimore, Maryland, United States of America  
Atherosclerosis, Chronic kidney disease, Diabetes, Heart failure, Hypertension, Insulin resistance, Lipoproteins

**Editorial Board Members**

**Matthew Allison**, University of California San Diego School of Medicine, La Jolla, California, United States of America  
Subclinical atherosclerosis, Body composition, Sedentary behavior, Women’s health, Race/ethnic disparities

**Marcello Arca**, University of Rome La Sapienza, Roma, Italy  
Atherosclerosis, Dyslipidemias, Lipoprotein metabolism, Lipid-lowering drugs, Cardiovascular disease prevention, Genetics

**Wilbert S. Aronow**, New York Medical College, Valhalla, New York, United States of America  
Hypertension, Dyslipidemia, Smoking, Cardiovascular disease

**Maurizio Averna**, University of Palermo, Palermo, Italy  
Dyslipidemia, Familial hypercholesterolemia, Metabolic conditions

**Maciej Banach**, Medical University of Lodz, Lodz, Poland  
Atherosclerosis, lipids, statins, PCSK9, cardiovascular disease prevention, risk stratification

**Seth Baum**, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, United States of America  
Clinical research, Prevention, Atherosclerosis, Lipids, Patient advocacy, Drug access

**Michael Blaha**, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America  
Cardiovascular Computed Tomography, Cardiovascular Disease, Preventive Cardiology

**Zachary T. Bloomgarden**, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America  
Diabetes, Lipids, Chronic kidney disease, Neuropathy

**Rachel Bond**, Creighton University School of Medicine, Omaha, Nebraska, United States of America

**Jan Borén**, University of Gothenburg, Gothenburg, Sweden  
Lipoproteins, Stable isotopes, Atherosclerosis, Lipid droplets, Cell biology, Ectopic lipid accumulation

**La Princess Brewer Brewer**, Mayo Clinic Preventive Cardiology Program, Rochester, Minnesota, United States of America  
Racial/ethnic health disparities, Health promotion, Community-based interventions, Cardiac rehabilitation, Psychosocial factors

**Matthew Budoff**, The Lundquist Institute, Torrance, California, United States of America  
Atherosclerosis, Lipids, Cardiac CT, Coronary artery calcium, Cardiovascular disease prevention

**Prakash Deedwania**, University of California San Francisco Fresno, Fresno, California, United States of America  
Diabetes, Metabolic syndrome & CVD, Statins & PCSK 9i and lipids, Newer anti diabetic drugs, Hypertension & CVD, Heart Failure prevention & treatment

**Bart Duell**, Oregon Health & Science University, Portland, Oregon, United States of America
Dyslipidemia, Familial hypercholesterolemia, Endocrinology, Diabetes

Daniel Duprez, University of Minnesota, Minneapolis, Minnesota, United States of America
Biomarkers, Lipids, Arterial stiffness, Hypertension, Markers of early CVD

Brian Ference, University of Cambridge School of Clinical Medicine, Cambridge, United Kingdom
Mendelian randomization, Atherosclerosis, Lipids, Risk factors, Cardiovascular disease prevention

Zlatko Fras, University Medical Center, Ljubljana, Slovenia
Atherosclerosis-related cardiovascular disease risk, Blood lipids, management, Coronary artery disease, Cardiac rehabilitation, Secondary prevention

Jacques Genest, McGill University, Montreal, Quebec, Canada
Atherosclerosis, Coronary artery disease, Lipids, Cholesterol, Lipoproteins, Lipoprotein metabolism, LDL, HDL, Prevention, PCSK9, Genetics

Ian Graham, The University of Dublin Trinity College, Dublin, Ireland
Natural history of coronary heart disease, Cardiovascular risk estimation, Blood lipids, Health policy and planning, Evaluation of therapies

Dongfeng Gu, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
Hypertension, Cardiovascular epidemiology, Diabetes

Rajeev Gupta, Eternal Heart Care Centre and Research Institute, Jaipur, India
Coronary heart disease, Epidemiology, Hypertension, Risk factors, Public health interventions

Mariko Harada-Shiba, National Cerebral and Cardiovascular Center, Suita, Japan
Lipoprotein, Lipid lowering drugs, Familial hypercholesterolemia, LDL receptor, PCSK9

Robert Hegele, Robarts Research Institute, London, Ontario, Canada
Genetics, Lipids, Hypercholesterolemia, Hypertriglyceridemia, Atherosclerosis

Heather Johnson, Boca Raton Regional Hospital Inc, Boca Raton, Florida, United States of America
Cardiovascular risk assessment, (resistant) hypertension, atherosclerosis, heart failure, prevention, women's health, pregnancy-related cardiovascular disease

Joshua Knowles, Stanford University, Stanford, California, United States of America
Familial hypercholesterolemia, Genetics, Insulin resistance, Type 2 diabetes

Steve Kopecky, Mayo Foundation for Medical Education and Research, Rochester, Minnesota, United States of America
How to Change Nutrition, Physical activity, Weight, Sleep, Stress/social, Lipids, Familial Hypercholesterolemia

Mikhail Kosiborod, Saint Luke's Health System, Kansas City, Missouri, United States of America
Diabetes and cardiovascular disease, Cardiometabolic and cardiorenal syndromes

Kornelia Kotseva, National University of Ireland Galway, Galway, Ireland
Primary and secondary cardiovascular disease prevention, Cardiovascular risk calculation, Lipids, Cardiac rehabilitation, Guidelines implementation

David Maron, Stanford University, Stanford, California, United States of America
Lipids, Coronary artery disease, Primary prevention, Secondary prevention, Optimal medical therapy

Seth Shay Martin, Johns Hopkins Hospital and Health System, Baltimore, Maryland, United States of America
Digital health, Precision medicine, Lipidology, LDL cholesterol

Anastasia Susie Mihailidou, Royal North Shore Hospital, St Leonards, Australia
Hypertension, blood pressure measurement, sex differences, cardiovascular endocrinology, sex hormones

Vijay Nambi, Baylor College of Medicine, Houston, Texas, United States of America
Biomarkers, Ultrasound, Prevention

Ann Marie Navar, UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER, Dallas, Texas, United States of America
Atherosclerosis, Lipids, Cardiovascular disease prevention, Epidemiology

Stephen Nicholls, Monash University, Clayton, Victoria, Australia
Atherosclerosis, Lipids, Imaging, Clinical trials, Prevention, Risk factors

Nathalie Pamir, Oregon Health & Science University, Portland, Oregon, United States of America
Atherosclerosis, Adipose tissue biology, Lipids, Lipoprotein metabolism, Proteomics, Cardiovascular disease prevention

Nopparat Panthongwiriya, BNH Hospital, Bangkok, Thailand
Atherosclerosis, Hypertension, Dyslipidemia, Cardiovascular disease prevention

Dan Piskorz, Cardiovascular Research Center of Sanatorio Británico SA, Rosario, Argentina
Hypertension, Cardiometabolic Disease, Diabetic Cardiomyopathy, Hypertensive Cardiopathy, Ambulatory Blood Pressure Monitoring

Nana Pogosova, National Medical Research Center, Moscow, Russian Federation
Prevention, Psychosocial, Hypertension, CHD, Cardiorenhabilitation

Paolo Raggi, University of Alberta, Edmonton, Alberta, Canada
Computed tomography angiography, Coronary artery calcium, Myocardial perfusion, Chronic kidney disease, Risk stratification, Atherosclerosis imaging
Jamal Rana, Kaiser Permanente, Oakland, California, United States of America
Cardiovascular disease prevention, Lipids, Diabetes, Subclinical atherosclerosis

Peter Reaven, Phoenix VA Health Care System, Phoenix, Arizona, United States of America
Diabetes, Glucose metabolism, Insulin resistance, Atherosclerosis, Lipids

Raoul Santos, University of Sao Paulo, Sào Paulo, Brazil
Familial Hypercholesterolemia, Imaging in Atherosclerosis, Preventive Cardiology

Douglas Schocken, Duke University, Durham, North Carolina, United States of America
Heart failure, Coronary artery disease, Preventive cardiology

Geeta Sikand, University of California Irvine School of Medicine, Irvine, California, United States of America
Cardiovascular nutrition, Medical nutrition therapy for dyslipidemia, Nutrition counseling, Diet and weight management

Neil Stone, Northwestern University - Chicago, Illinois, United States of America
Lipids, Lipoproteins, Clinical trials, Guidelines, Nutrition

S. Lale Tokgözoğlu, Hacettepe University Department of Cardiology, Ankara, Turkey
Lipids, Prevention, Atherosclerosis, LDL-cholesterol

Gumpanart Veerakul, Bangkok Hospital, Bangkok, Thailand
Dyslipidemia, Familial hypercholesterolemia, Brugada syndrome, and Biomarkers

Salim Virani, Baylor College of Medicine, Houston, Texas, United States of America
Cardiovascular Outcomes and Guidelines

Karol Watson, University of California Los Angeles, Los Angeles, California, United States of America
Vascular biology, Prevention, Hypertension, Lipidology

Gerald Watts, The University of Western Australia, Perth, Western Australia, Australia
Lipids, Familial hypercholesterolaemia, Lp(a), Inherited heart disease, Obesity, Metabolism

Nanette Wenger, Emory University School of Medicine, Atlanta, Georgia, United States of America
Heart disease in women, Heart disease in the elderly, Cardiac rehabilitation, Coronary disease prevention, and Contemporary cardiac care

Michael Wilkinson, University of California San Diego School of Medicine, La Jolla, California, United States of America
Lipidology, Diet, Lifestyle, Intermittent Fasting, Cardiometabolic diseases

Peter Wilson, Emory University, Atlanta, Georgia, United States of America
Atherosclerosis, Lipids, Lipoprotein metabolism, PCSK9, Cardiovascular disease prevention

Eugene Yang, UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE, Seattle, Washington, United States of America
Atherosclerosis, Coronary Heart Disease, Dyslipidemia, Hypertension, Prevention and Risk Assessment

Dong Zhao, Capital Medical University, Beijing, China
Atherosclerosis, Risk factors, Risk assessment, Cardiovascular disease prevention
GUIDE FOR AUTHORS

INTRODUCTION

Introduction
Published quarterly, The American Journal of Preventive Cardiology is the official journal of the American Society of Preventive Cardiology. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research and reviews are published on epidemiology and clinical studies on risk factors, behavioral and pharmacologic interventions aimed at the primary and secondary prevention of cardiovascular diseases and related conditions, as well as the promotion of individual and community cardiovascular health.

The journal publishes both original research and review papers that address the key aspects of preventive cardiology, including the primary and secondary prevention of cardiovascular disease and related conditions including both behavioral (e.g., smoking, obesity, diet, and physical activity) and clinical (e.g., dyslipidemia, hypertension, and diabetes) aspects. Papers also address educational and other initiatives and methods aimed at improving the ability of cardiologists and healthcare professionals to provide effective clinical prevention and public health services. The journal also publishes guidelines and official policy statements from the Society, review articles, media reviews, and editorials. Finally, the journal periodically publishes special theme issues devoted to areas of current interest to the cardiac prevention community. Also included are editorials, readers' comments, and abstracts from the annual ASPC scientific sessions.

BEFORE YOU BEGIN

Ethics in publishing
Please see our information on Ethics in publishing.

Human rights
If the work reported involves the use of human subjects, the author should ensure that the work described has been carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki) for experiments involving humans http://www.wma.net/en/30publications/10policies/b3/index.html; Uniform Requirements for manuscripts submitted to Biomedical journals http://www.icmje.org. The author should include a statement in the manuscript that informed consent was obtained for experimentation with human subjects. The privacy rights of human subjects must always be observed.

Declaration of interest
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted. 2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. More information.

For a generic template of the 'Declaration of Interest/Author Agreement' form to upload with your submission please click on the following link: Template

Submission declaration and verification
Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see ‘Multiple, redundant or concurrent publication’ for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright-holder. To verify originality, your article may be checked by the originality detection service Crossref Similarity Check.
Preprints
Please note that preprints can be shared anywhere at any time, in line with Elsevier's sharing policy. Sharing your preprints e.g. on a preprint server will not count as prior publication (see 'Multiple, redundant or concurrent publication' for more information).

Use of inclusive language
Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Content should make no assumptions about the beliefs or commitments of any reader; contain nothing which might imply that one individual is superior to another on the grounds of age, gender, race, ethnicity, culture, sexual orientation, disability or health condition; and use inclusive language throughout. Authors should ensure that writing is free from bias, stereotypes, slang, reference to dominant culture and/or cultural assumptions. We advise to seek gender neutrality by using plural nouns ("clinicians, patients/clients") as default/wherever possible to avoid using "he, she," or "he/she." We recommend avoiding the use of descriptors that refer to personal attributes such as age, gender, race, ethnicity, culture, sexual orientation, disability or health condition unless they are relevant and valid. These guidelines are meant as a point of reference to help identify appropriate language but are by no means exhaustive or definitive.

Author contributions
For transparency, we encourage authors to submit an author statement file outlining their individual contributions to the paper using the relevant CRediT roles: Conceptualization; Data curation; Formal analysis; Funding acquisition; Investigation; Methodology; Project administration; Resources; Software; Supervision; Validation; Visualization; Roles/Writing - original draft; Writing - review & editing. Authorship statements should be formatted with the names of authors first and CRediT role(s) following. More details and an example

Changes to authorship
Authors are expected to consider carefully the list and order of authors before submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only before the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the corresponding author: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors after the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

Article transfer service
This journal is part of our Article Transfer Service. This means that if the article is not accepted for publication in AJPC, the Editor in Chief may suggest the possibility of transferring it to another journal for consideration for publication. You may accept or decline; if you accept, your article will be transferred automatically on your behalf with no need to reformat. More information about this can be found here: https://www.elsevier.com/authors/article-transfer-service.

Role of the Funding Source
Please identify who provided financial support for the research and/or preparation of the article and briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis, and interpretation of data; in writing the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated. Please see https://www.elsevier.com/funding.

Funding Body Agreements and Policies
Elsevier has established agreements and developed policies to allow authors whose articles appear in journals published by Elsevier to comply with potential manuscript archiving requirements as specified as conditions of their grant awards. To learn more about existing agreements and policies please visit https://www.elsevier.com/fundingbodies.

Open access
Please visit our Open Access page for more information.
A limited number of partial or full waivers of the article processing fee are available upon request (and may be granted according to various criteria including whether the article was invited, quality of the article, indicated financial need such as from a developing country or where the processing fees are not otherwise covered by another source).

**Language services**
Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the English language editing service available from Elsevier's WebShop. See [https://webshop.elsevier.com/language-editing-services/language-editing/](https://webshop.elsevier.com/language-editing-services/language-editing/) or visit our customer support site [https://service.elsevier.com](https://service.elsevier.com) for more information.

**Submission**
Submission to this journal for original research contributions, review articles, brief reports, and editorials, proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts source files to a single PDF file of the article, which is used in the peer-review process. Please note that even though manuscript source files are converted to PDF files at submission for the review process, these source files are needed for further processing after acceptance. All correspondence, including notification of the Editor's decision and requests for revision, takes place by e-mail, eliminating the need for a paper trail.

**Submit your article**
Please submit your article via [https://editorialmanager.com/ajpc](https://editorialmanager.com/ajpc)

**PREPARATION**

**NEW SUBMISSIONS**
Submission to this journal proceeds totally online and you will be guided stepwise through the creation and uploading of your files. The system automatically converts your files to a single PDF file, which is used in the peer-review process.

As part of the Your Paper Your Way service, you may choose to submit your manuscript as a single file to be used in the refereeing process. This can be a PDF file or a Word document, in any format or layout that can be used by referees to evaluate your manuscript. It should contain high enough quality figures for refereeing. If you prefer to do so, you may still provide all or some of the source files at the initial submission. Please note that individual figure files larger than 10 MB must be uploaded separately.

**References**
There are no strict requirements on reference formatting at submission. References can be in any style or format as long as the style is consistent. Where applicable, author(s) name(s), journal title/book title, chapter title/article title, year of publication, volume number/book chapter and the article number or pagination must be present. Use of DOI is highly encouraged. The reference style used by the journal will be applied to the accepted article by Elsevier at the proof stage. Note that missing data will be highlighted at proof stage for the author to correct.

**Formatting requirements**
There are no strict formatting requirements but all manuscripts must contain the essential elements needed to convey your manuscript, for example Abstract, Keywords, Introduction, Materials and Methods, Results, Conclusions, Artwork and Tables with Captions.

If your article includes any Videos and/or other Supplementary material, this should be included in your initial submission for peer review purposes.

Divide the article into clearly defined sections.

**Figures and tables embedded in text**
Please ensure the figures and the tables included in the single file are placed next to the relevant text in the manuscript, rather than at the bottom or the top of the file. The corresponding caption should be placed directly below the figure or table.

**Peer review**
This journal operates a double blind review process. All contributions will be initially assessed by the Editor and/or Executive Editor for suitability for the journal. Papers deemed suitable are then typically forwarded to an Associate Editor and/or sent to a minimum of two independent expert reviewers to
assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor’s decision is final. More information on types of peer review

**MANUSCRIPTS** are received with the understanding that they are submitted solely to *The American Journal of Preventive Cardiology* and, that the work has not been previously published, and that the data in the manuscripts have been reviewed by all authors, who agree with the analyses of the data and the conclusions reached in the manuscript. Statements in articles are the responsibility of the authors. The Journal does not accept original articles involving animal research.

**Inhouse submissions from Editors:** Editors are not involved in decisions about papers which they write themselves or have been written by family members or colleagues or which relate to products or services in which the Editor has an interest. Any such submission is subject to all of the journal’s usual procedures, with peer review handled independently of the relevant editor and their research groups.

Papers written by Editors should have a standard footnote like this:

Given his role as [Guest] Editor [in Chief], [NAME of Editor] had no involvement in the peer-review of this article and has no access to information regarding its peer-review. Full responsibility for the editorial process for this article was delegated to [NAME of delegated editor].

Manuscript type should be indicated where prompted on the on-line submission site and may include

1) **Original research contribution** (usually under 4000 words but exceptions can be made)

2) **State-of-the-art review** (usually under 5000 words but exceptions can be made),

3) **Commentary** (usually under 2000 words and 1-2 tables/figures) and may include perspectives, viewpoints and practice experiences in diverse settings and around the world,

4) **Short report** (usually under 2000 words plus 1-2 tables/figures and references),

5) **Clinical practice statement or recommendations** (no word limit),

6) **ASPC news** (e.g., President's message, advertisement, abstracts, or other news)

*All of the word count does not include references, tables, figures, and acknowledgements.

Please identify one of your figures as Central Illustration.

All new manuscripts, including Readers' Comments and Errata, must be submitted through *The American Journal of Preventive Cardiology* submission site: [https://editorialmanager.com/ajpc](https://editorialmanager.com/ajpc). Authors are requested to submit the text, tables, and figures in electronic form to this address. The Publisher and Editors regret that they are not able to consider submissions that do not follow these procedures. Please include the corresponding author's phone and email address. The cover letter should state precisely and concisely the significance and uniqueness of the work in the authors' view. The authors may state the extent of any concessions they are prepared to make (for example, the elimination of 1 or more figures or tables or a portion of the text) to increase the likelihood of publication of their work in the Journal. If possible, names and email addresses should be provided of non-local experts who, in the view of the author(s), could provide objective and informed reviews of their work. The names of investigators considered unlikely to give nonbiased reviews of their work also may be submitted. This request is honored.

Please note that an editable file is needed for production purposes after acceptance, and we ask that you submit source files in the event your manuscript is accepted.

Study recent past issues of the Journal for format. Arrange the paper as follows: (1) title page, which should include the title, the full names and academic degrees of the authors, and current affiliations of all authors; (2) abstract; (3) text; (4) acknowledgement; (5) references; (6) figure legends; (7) tables; and (8) figures. Number the title page as 1, abstract page as 2 with the introduction beginning on page #3 and so forth. Type double-spaced (including references) with at least 25-mm (1-inch) margins, sized for 8.5 x 11 inch paper. Times New Roman or Arial Font sized 11 or
12 are recommended. Files should be labeled with appropriate and descriptive file names. Upload the manuscript (including tables) as one file and figures as separate files. Any supplementary on-line material should also be uploaded separately. Complete instructions for electronic artwork submission can be found on the Author Gateway, accessible through the journal home page.

**Title Page and Abstract**

For the complete title page, include the full first or middle and last names of all authors. List the current affiliations of all authors and link author names and affiliations by "a," "b," "c," etc., after the author names and before the affiliation. Provide information about grant support if necessary, including the location (City/state/country). If work described is supported by a grant from a pharmaceutical company, that fact should be stated on the title page. Add at the bottom the phrase "Corresponding author" followed a telephone number, email address, and mailing address. Add a 2-to 6-word running head. Limit the abstract to 300 words or a single page. For original research articles, abstracts should be formatted with the following sections: Objective, Methods, Results, Conclusion. List 2 to 4 key words for subject indexing at the end of the abstract.

**Highlights**

Highlights are optional yet highly encouraged for this journal, as they increase the discoverability of your article via search engines. They consist of a short collection of bullet points that capture the novel results of your research as well as new methods that were used during the study (if any). Please have a look at the examples here: example Highlights.

Highlights should be submitted in a separate editable file in the online submission system. Please use 'Highlights' in the file name and include 3 to 5 bullet points (maximum 85 characters, including spaces, per bullet point).

**Style**

Use the required 3 major headings throughout the body of the text, such as Methods, Results, and Discussion. Do not use subheadings under these headings. Tables, figures, and references must be cited in numerical order throughout the manuscript. Abbreviations are permitted, but usually should be limited to 10 per manuscript, and then they must be used on every page of the manuscript after they are initially spelled out (followed by the abbreviation) in both abstract and introduction. Use generic names of drugs. Do not spell out any number, including those less than 10, except when used for opening a sentence, but try not to begin sentences with a numer. Use symbols for less than <, greater than > and percent (%). Indent all paragraphs after the abstract and introduction. Both the abstract and introduction should be a single paragraph. Consult the Uniform Requirements for Manuscripts Submitted to Biomedical Journals, published in *The Annals of Internal Medicine* June 1982;96:766-771, and also the *Stylebook/Editorial Manual of the AMA*.

**Figures**

Number figures in order in which they are mentioned in the text. Type figure legends on a separate page, double-spaced, after the references within the text document. Clearly mark figures with a, b, c, top, bottom, right and left.

Download each figure as a separate file (.tif .eps, .jpeg formats are preferred, although .ppt, .xls, .pdf, and .doc files are accepted.). Do not import figures into the text document. Complete instructions for electronic artwork submission can be found on the Author Gateway, accessible through the journal home page. Submit written permission from the publisher and author to reproduce any previously published figures. Limit figures to the number necessary to present the message clearly. Figure resolution must be a minimum of 300 dpi. Type figure legends on a separate page, double-spaced after the references. Identify at the end of each legend and in alphabetical order all abbreviations in the figure. The cost of color reproduction must be paid by the author.

**Tables**

Number each table in Arabic numerals (Table 1, 2, etc.) and title each table. Tables may be included within the main text document or as separately uploaded Word files. Identify in alphabetical order at the bottom of the table all abbreviations used. When tabulating numbers of patients, use no more
than 2 lines preferably only 1 line across per patient. Use a plus sign (+) to indicate "positive" or "present" a zero (0) for "negative" or "absent" and a dash (-) for "no information available" or "not done." Do not use "yes", "no" or "none."

Readers’ Comments

The author who submits a 'letter' should provide a cover letter to the Editor in Chief explaining why the letter should be published. The letter (as well as references) should be double-spaced, and limited, with few exceptions, to 2 pages. A title for the letter should be provided at the top of the page. A title page is not required. At the end of the letter, the writer's full name, highest degree, and city and state (or country if outside the US) should be provided followed by the date of submission. The author's institution should not be included. A letter concerning a particular article in the Journal must be received (from authors within the US) within 2 months of the article's publication.

Data references

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

Double anonymized review

This journal uses double anonymized review, which means the identities of the authors are concealed from the reviewers, and vice versa. More information is available on our website. To facilitate this, please include the following separately:

Title page (with author details): This should include the title, authors' names, affiliations, acknowledgements and any Declaration of Interest statement, and a complete address for the corresponding author including an e-mail address.

Anonymized manuscript (no author details): The main body of the paper (including the references, figures, tables and any acknowledgements) should not include any identifying information, such as the authors' names or affiliations.

REVISED SUBMISSIONS

Use of word processing software

Regardless of the file format of the original submission, at revision you must provide us with an editable file of the entire article. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the Guide to Publishing with Elsevier). See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

Reference management software

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support Citation Style Language styles, such as Mendeley. Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. More information on how to remove field codes from different reference management software.

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

http://open.mendeley.com/use-citation-style/the-american-journal-of-cardiology

When preparing your manuscript, you will then be able to select this style using the Mendeley plug-ins for Microsoft Word or LibreOffice.
Reference style
List all authors (up to 6 must be included; if there are more than 6 authors, the first 3 followed by et al. should be listed), year, volume, and inclusive pages for all journal references, and specific page numbers for all book references as shown below. Do not use periods after authors’ initials or after abbreviations for titles of journals. Check Index Medicus or Annals of Internal Medicine (June 1982) as cited above for journal titles/abbreviations. Personal communications and unpublished observations do not constitute references, but may be mentioned within the text. Articles with incorrect reference formats will not be processed. All authors up to 6 must be included; if there are more than 6 authors the first 3 followed by et al. should be listed. All references must be typed out at the end of the article on a new page.


Please note: We will be listing the reference style for AJPC in Clarivate EndNote soon. Until then, please use the reference style of "Progress in Pediatric Cardiology? as an example.

**Video**
Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including ScienceDirect. Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our video instruction pages. Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Data visualization**
Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplementary material**
Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**
This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.
Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

**Data linking**

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the database linking page.

For supported data repositories a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

**Mendeley Data**

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the Mendeley Data for journals page.

**Data statement**

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the Data Statement page.

**Submission checklist**

Before you submit your article, please be sure that:

One author has been designated as the corresponding author with contact details: E-mail address
Full postal address Phone numbers

All necessary files have been uploaded, and contain:
All illustration legends All tables (including title, description, footnotes)
Manuscript has been spell-checked and grammar-checked
References are in the correct format for this journal

All references mentioned in the Reference list are cited in the text, and vice versa
Permission has been obtained for use of copyrighted material from other sources (including the Web) Color illustrations are clearly marked as being intended for color reproduction on the Web (free of charge) and in print, or to be reproduced in color on the Web (free of charge) and in black-and-white in print

If only color on the Web is required, black-and-white versions of the illustrations are also supplied for printing purposes

For any further information please visit our customer support site at https://service.elsevier.com.

**AFTER ACCEPTANCE**

**Use of the Digital Object Identifier**

The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI is a unique alpha-numeric character string assigned to a document by the publisher upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal medium for citing a document, particularly articles in press, because they have not yet received their full bibliographic information.

Example of a correctly given DOI (in URL format; here an article in the journal Physics Letters B):
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author or a link will be provided in the e-mail so that author can download the files. The PDF proofs can be annotated, for which you will need to download Adobe Reader version 7 (or higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files will accompany the proofs (also given online). The exact system requirements are given at the Adobe site: http://www.adobe.com/products/reader/tech-specs.html. If you do not wish to use the PDF annotations function, you may list the corrections (including replies to the query form) and return them to Elsevier in an e-mail. Please list your corrections quoting line number. If this is not possible, then mark the corrections and any other comments (including replies to the query form) on a printout of your proof and return by fax, or scan the pages and send by e-mail or by post. Please use this proof only for checking the typesetting, editing, completeness, and correctness of the text, tables, and illustrations. Significant changes to the article as accepted for publication will be considered at this stage only with permission from the Editor. We will do everything possible to get your article published quickly and accurately - please let us have all your corrections within 48 hours. It is important to ensure that all corrections are sent back to us in one communication: please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility. Note that Elsevier may proceed with the publication of your article if no response is received.

Online proof correction
Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor. Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF. We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

Offprints
The corresponding author will, at no cost, receive a customized Share Link providing 50 days free access to the final published version of the article on ScienceDirect. The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Author Services. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

For inquiries relating to the submission of articles (including electronic submission) please visit this journal's homepage (https://editorialmanager.com/ajpc). For detailed instructions on the preparation of electronic artwork, please visit https://www.elsevier.com/artworkinstructions. Contact details for questions arising after acceptance of an article, especially those relating to proofs, will be provided by the publisher. You can track accepted articles at https://www.elsevier.com/trackarticle. You can also check our Author FAQs at https://www.elsevier.com/authorFAQ and/or contact Customer Support via https://service.elsevier.com.

Reprints
Price schedules and order cards for reprints are mailed to the author upon publication of the article. Individual reprints must be obtained through the author.

© Copyright 2018 Elsevier | https://www.elsevier.com